Literature DB >> 16322943

TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis.

V Kolachala1, V Asamoah, L Wang, T S Obertone, T R Ziegler, D Merlin, S V Sitaraman.   

Abstract

Adenosine is an endogenous signaling molecule upregulated during inflammatory conditions. Acting through the A2b receptor (A2bR), the predominant adenosine receptor in human colonic epithelia, adenosine has been directly implicated in immune and inflammatory responses in the intestine. Little is known about expression and regulation of A2bR during inflammation. Tumor necrosis factor alpha (TNF-alpha) is highly upregulated during chronic and acute inflammatory diseases. This study examined the expression of A2bR during colitis and studied effects of TNF-alpha on A2bR expression, signaling and function. Results demonstrated that A2bR expression increases during active colitis. TNF-alpha pretreatment of intestinal epithelial cells increased A2bR messenger RNA and protein expression. TNF-alpha significantly increased adenosine-induced membrane recruitment of A2bR and cyclic adenosine monophosphate downstream signaling. Further, TNF-alpha potentiated adenosine-induced shortcircuit current and fibronectin secretion. In conclusion, we demonstrated that TNF-alpha is an important regulator of A2bR, and during inflammation, upregulation of TNF-alpha may potentiate adenosine-mediated responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322943     DOI: 10.1007/s00018-005-5328-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  53 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

2.  Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.

Authors:  Sebastian Michael; Heba Abdel-Aziz; Dieter Weiser; Christa E Müller; Olaf Kelber; Karen Nieber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-10       Impact factor: 3.000

3.  A(₂B)AR expression in non-immune cells plays an important role in the development of murine colitis.

Authors:  Sarah A Ingersoll; Hamed Laroui; Vasantha L Kolachala; Lixin Wang; Pallavi Garg; Timothy L Denning; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Dig Liver Dis       Date:  2012-06-19       Impact factor: 4.088

Review 4.  Regulation of lymphocyte function by adenosine.

Authors:  Joel Linden; Caglar Cekic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-05       Impact factor: 8.311

Review 5.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 6.  A(2B) adenosine receptors in immunity and inflammation.

Authors:  György Haskó; Balázs Csóka; Zoltán H Németh; E Sylvester Vizi; Pál Pacher
Journal:  Trends Immunol       Date:  2009-05-07       Impact factor: 16.687

Review 7.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 8.  The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.

Authors:  Anna Eisenstein; Shenia Patterson; Katya Ravid
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

9.  Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats.

Authors:  L Antonioli; M Fornai; O Awwad; G Giustarini; C Pellegrini; M Tuccori; V Caputi; M Qesari; I Castagliuolo; P Brun; M C Giron; C Scarpignato; C Blandizzi; R Colucci
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

10.  Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation.

Authors:  Wei Wei; Changsheng Du; Jie Lv; Guixian Zhao; Zhenxin Li; Zhiying Wu; György Haskó; Xin Xie
Journal:  J Immunol       Date:  2012-12-05       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.